Unknown PHASE2 INTERVENTIONAL 2-arm NCT03290820

Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients

Aspirin Improve Survival of Patients With N2-3 Nasopharyngeal Carcinoma: A Phase 2 Prospective Randomized Controlled Trial

Sponsor: Sun Yat-sen University

Conditions Nasopharyngeal Carcinoma

Interventions Aspirin Concurrent chemotherapy Radiotherapy

Updated 6 times since 2017 Last updated: Oct 25, 2017 Started: Jan 1, 2018 Primary completion: Sep 30, 2024 Completion: Sep 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Nasopharyngeal Carcinoma and is currently ongoing. Sun Yat-sen University leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Nov 2024 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
Jun 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Oct 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China